9,13-Dihydroxy-8,14,19-trimethoxy-4,10,12,16-tetramethyl-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaene-3,20,22-trione

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 大环内酰胺类
• 英文名称: 9,13-Dihydroxy-8,14,19-trimethoxy-4,10,12,16-tetramethyl-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaene-3,20,22-trione
• 化学式: C₂₈H₃₉NO₈
• 分子量: 517.6
• InChiKey: AZMUWZBGFKDVCZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  37
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  131
• 氢给体数：
  3
• 氢受体数：
  8

文献信息

• [EN] TUMOUR PHENOTYPE PATIENT SELECTION METHOD<br/>[FR] PROCÉDÉ DE SÉLECTION DE PATIENTS SELON LEUR PHÉNOTYPE TUMORAL
  申请人：ASTRAZENECA AB

  公开号：WO2012052757A1

  公开（公告）日：2012-04-26

  The present invention relates to a method for stratifying cancer patients according to the cellular phenotype of the tumour based and in particular, according to the presence of stroma and/or location of tumour vessels within the tumour or stromal compartments of a tumour. This patient stratification permits identification of patients whose tumours are more likely to be responsive to treatment with anti-cancer drugs, such as Vascular Endothelial Growth Factors (VEGF) signalling inhibitors. This invention therefore provides personalised healthcare opportunities in the cancer arena.